LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Top 50 High-Quality Dividend Growth Stocks For November 2026

Seeking Alpha

11:12 AM | Saturday | Nov 14, 2026

news photo
Loading...

I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.

Read full article redirect
11:12 AM | Saturday | Nov 14, 2026

Top 50 High-Quality Dividend Growth Stocks For November 2026

Seeking Alpha

I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.

Read full article arrow
News Thumbnail
7:23 AM | Saturday | Nov 14, 2026

Bernicke Wealth Management Ltd. Makes New $5 Million Investment in Eli Lilly and Company $LLY

Defense World

Bernicke Wealth Management Ltd. purchased a new position in shares of Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,322 shares of the company's stock, valued at approximately $5,001,000. Eli Lilly and Company accounts for

Read full article arrow
News Thumbnail
12:16 PM | Friday | Nov 13, 2026

HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs

Zacks Investment Research

Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.

Read full article arrow
News Thumbnail
10:16 AM | Friday | Nov 13, 2026

4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

Zacks Investment Research

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.

Read full article arrow
News Thumbnail
6:10 AM | Friday | Nov 13, 2026

Mapping the Market: Eli Lilly shares ready to rally again

Reuters

Mapping the Market: Eli Lilly shares ready to rally again

Read full article arrow
News Thumbnail
2:22 AM | Thursday | Nov 12, 2026

China approves Eli Lilly's weight loss pill orforglipron

Reuters

China approves Eli Lilly's weight loss pill orforglipron

Read full article arrow
News Thumbnail
9:56 AM | Wednesday | Nov 11, 2026

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

Benzinga

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure and Merck & Co‘s (NYSE:MRK) and Bristol-Myers Squibb Co‘s (NYSE:BMY) confronting a potentially bigger test in the years ahead.

Read full article arrow
News Thumbnail
9:45 AM | Wednesday | Nov 11, 2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

PRNewsWire

Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpoint Detailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology  INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with... Read more

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Nov 10, 2026

10 Dividend Growth Stocks: November 2026

Seeking Alpha

In this monthly series, I rank a selection of dividend growth stocks and present the top 10 for consideration. To rank stocks, I sort candidates by quality score. This month's top 10, led by AMAT, LRCX, LLY, and AVGO, are compounders with 5-year trailing total returns of 12%+ and trade at or below fair value. Quality is paramount: all top 10 stocks are rated Exceptional or Excellent, with strong 9F Quality Scores and robust dividend safety, growth, and profitability metrics.

Read full article arrow
News Thumbnail
9:55 AM | Monday | Nov 9, 2026

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

Zacks Investment Research

NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.

Read full article arrow
News Thumbnail